FDA reinspection of Sun’s troubled Halol plant said to be underway

Sun Pharmaceutical's Halol facility in India.

The FDA reinspection of Sun Pharmaceutical’s troubled Halol plant in India is reported to be underway, as the drug manufacturing site is seen as a critical revenue stream for the company.

The regulatory agency inspection, which Sun requested earlier this year, began last week, The Economic Times reported, citing three unnamed sources.

Last year, the FDA slapped the facility with a warning letter after a previous inspection that listed 20 critical observations at the operations of the plant.

Free Webinar

Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This webinar will discuss the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

Sun Pharma declined to comment to the publication on reports of the latest inspection.

The Halol site is viewed by Sun as a critical element in the company’s goals to increase its growth in the U.S. market. The Halol facility, which produces a gamut of products from tablets to nasal sprays, accounts for an estimated 15% of the company’s revenues in the U.S.

In July, the FDA said Sun had begun recalling 16,085 bottles of the antidepressant bupropion hydrochloride extended-release tablets manufactured at the Halol plant because they failed specifications for dissolution. The recall was initiated in June.

Sun saw sales slip after the U.S. regulatory agency cited the Halol plant with a Form 483 in December 2014. The agency issued a warning letter at that time for a number of quality and data-integrity issues, and the drugmaker recalled a number of products as a result.

Suggested Articles

Novartis' Sandoz doubled down in Japan as Lupin retreated. Dr. Reddy's posted a loss tied to its Zantac recall. Aslan's varlitinib failed again.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.